Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The goal of the study is to investigate the impact of a 4 week treatment with pioglitazone
(in comparison to placebo) on biomarkers for atherosclerosis and cardiovascular risk, as well
as the degree of activation of the immune system, when given on top of an anti-diabetic
treatment (metformin and/or sulfonylurea drugs) that has already resulted in good glycemic
control.
Phase:
Phase 4
Details
Lead Sponsor:
IKFE Institute for Clinical Research and Development
Collaborators:
Heidelberg University Johannes Gutenberg University Mainz Takeda